| Recruiting | Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell NCT06928662 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Tr NCT05589896 | Ossium Health, Inc. | Phase 1 / Phase 2 |
| Recruiting | Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies NCT05476770 | Therapeutic Advances in Childhood Leukemia Consortium | Phase 1 |
| Withdrawn | Cryopreserved MMUD BM With PTCy for Hematologic Malignancies NCT05170828 | Ossium Health, Inc. | Phase 1 |
| Suspended | Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) NCT05322850 | University of Florida | Phase 1 / Phase 2 |
| Completed | A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia NCT05326516 | Syndax Pharmaceuticals | Phase 1 |
| Recruiting | Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Bloo NCT03779854 | Fred Hutchinson Cancer Center | Phase 2 |
| Recruiting | HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After NCT03326921 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Rela NCT02220985 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Di NCT02135874 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in NCT01858740 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Le NCT01869777 | Wake Forest University Health Sciences | N/A |
| Completed | MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia NCT01231919 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies NCT01273766 | Wake Forest University Health Sciences | Phase 2 |
| Active Not Recruiting | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic NCT01199562 | City of Hope Medical Center | — |
| Terminated | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01028716 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Canc NCT01053494 | Wake Forest University Health Sciences | N/A |
| Completed | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy NCT00890747 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating NCT00933985 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute NCT00557193 | Children's Oncology Group | Phase 3 |
| Completed | GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplast NCT00459212 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Structural Imaging and Cognitive Functions in Adult Stem Cell Transplant Recipients Treated With Chemotherapy NCT00606216 | Memorial Sloan Kettering Cancer Center | — |
| Terminated | Sunitinib in Treating Patients With Idiopathic Myelofibrosis NCT00387426 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofe NCT00118352 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic NCT00098826 | National Cancer Institute (NCI) | Phase 1 |
| Completed | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors o NCT00079404 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With NCT00898079 | Children's Oncology Group | — |
| Completed | Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia NCT00061945 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction NCT00025415 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Imm NCT00014235 | Fred Hutchinson Cancer Center | N/A |
| Completed | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporin NCT00006251 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenola NCT00112593 | Fred Hutchinson Cancer Center | N/A |